Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Kinaxis raises 2026 revenue forecast to USD 640 million-650 million

Kinaxis raises 2026 revenue forecast to USD 640 million-650 million

BitgetBitget2026/11/05 13:43
  • Kinaxis raised fiscal 2026 revenue guidance to USD 640 million–USD 650 million from USD 625 million–USD 640 million.
  • SaaS revenue growth is forecast at 20%–21%, up from 18%–20% previously.
  • Adjusted EBITDA margin is expected to reach 26.5%–27.5%, versus prior guidance of 25%–26%.
  • Third-quarter revenue rose 19% year over year to USD 160.26 million.
  • Currency movements are expected to reduce revenue by USD 3.5 million–USD 4 million and SaaS revenue by USD 2 million–USD 2.5 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kinaxis Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss